GEN Exclusives

More »

GEN News Highlights

More »
Jun 4, 2012

Telormedix, Foamix Win €950K to Develop Foam-Based Skin Cancer Treatment

  • Telormedix and Foamix have been awarded just shy of €950,000 (slightly below $1.2 million) under the EU’s Eurostars program to fund development of a foam-based topical treatment for skin cancer based on Telormedix’s TMX-202 candidate. Researchers at the Charité-Universitätsmedizin Berlin and the German Cancer Research Center (DKFZ) will collaborate on the two-year TOSCA project, which will study the efficacy and safety of the foam formulation using preclinical animal models.

    Swiss firm Telormedix is focused on the development of innate immune system-modulating drugs for treating cancer and autoimmune diseases. TMX-202 is a TLR7-targeted agonist discovered through a collaboration with the University of California, San Diego. The compound is in development for the potential treatment of dermatological cancers, actinic keratosis, and genital warts.

    Telormedix’s lead candidate, TMX-101, is a small molecule in development for the treatment of superficial bladder cancer. The compound is a known immunomodulatory molecule that has previously demonstrated clinical efficacy in oncological and viral diseases.

    Israel-based Foamix is a clinical-stage specialty pharma company exploiting its topical foam and OilGel™ technologies in house and through commercial partnerships for the development of products for dermatology, gynecology, ophthalmology, wounds, and burn applications. The firm’s first product, the foam-based psoriasis treatment, Scytera™, was launched by Promius Pharmaceuticals in the U.S. in 2009.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Ebola Vaccines

When do you think an Ebola vaccine will be available for the general public?